97278-64-3

Upstream product

• 85115-10-2 3-amino-1,2,3,4-tetrahydroquinolin-2-one 
• 710-11-2 2-oxo-4-phenylbutyric acid 
• 105-36-2 ethyl bromoacetate 
• 97278-62-1 3-<(1-carbethoxy-3-phenylpropyl)amino>-1,2,3,4-tetrahydroquinolin-2-one 

Downstream Products

• 97293-68-0 (R)-2-((R)-1-Carboxymethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-3-ylamino)-4-phenyl-butyric acid; hydrochloride 
• 97278-66-5 (S)-2-((R)-1-Carboxymethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-3-ylamino)-4-phenyl-butyric acid; hydrochloride 

Relevant academic research and scientific papers

Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme

Syntheses of the potent angiotensin converting enzyme inhibitor (3S)-1-(carboxymethyl)-3-[[(1S)-1-carboxy-3-phenylpropyl]amino]-2,3,4,5 -tetrahydro-1H-[1]benzazepin-2-one (CGS 14831) and the related monoester prodrug (17a; CGS 14824A) are described together with preparative details for six- and eight-membered ring analogues. Inhibitory potencies and in vivo biological activity of the compounds are discussed. The data indicate that 17a has a biological profile comparable to that of enalapril.